MIRM stock gains on strong Q2 2026 revenue growth

MIRM stock is trading near the 100 dollar mark as Mirum Pharmaceuticals posts double digit Q2 2026 revenue growth and raises its 2026 outlook, with the latest price data pointing to continued investor interest.

MIRM stock of Mirum Pharmaceuticals, Inc. (ISIN US60471A1034) is trading around 100 dollars per share as of September 5, 2026, supported by robust second quarter 2026 revenue growth and a higher full year outlook according to recent market data and company figures.

Q2 2026 earnings show revenue beat

According to data compiled by Yahoo Finance, Mirum Pharmaceuticals reported revenue of 176.24 million USD in the second quarter of fiscal year 2026, while posting an earnings loss of 67.23 million USD for the same period.

A separate overview on MarketBeat highlights that Mirum Pharmaceuticals generated 176.24 million USD revenue in the latest quarter versus a consensus estimate of 166.33 million USD, meaning the company beat revenue expectations by about 10 million USD.

The same MarketBeat article notes that Mirum Pharmaceuticals reported a loss per share of 1.06 USD in this quarter, which was below the consensus expectation of a 0.74 USD loss per share, indicating that while top line momentum was strong, profitability lagged what analysts had anticipated.

Revenue growth and margin profile

MarketBeat also reports that Mirum Pharmaceuticals increased its quarterly revenue by 37.9 percent year on year in the latest reported quarter, demonstrating strong growth compared with the same period in the prior year, when the company earned significantly lower revenue and recorded a 0.12 USD loss per share.

Per the Yahoo Finance key figures page for Mirum Pharmaceuticals, the profit margin for the second quarter of fiscal year 2026 stands at negative 38.14 percent, underscoring that the company remains loss making despite the strong revenue trajectory and improved scale.

In addition, Yahoo Finance lists trailing twelve month earnings per share for Mirum Pharmaceuticals at negative 14.08 USD, while analysts in the MarketBeat coverage expect the company to post a full year 2026 earnings per share of negative 1.31 USD, suggesting that losses are expected to narrow compared with the longer term trailing figure.

Analyst and market reaction around the 100 dollar level

The Mirum Pharmaceuticals quote page on Yahoo Finance shows that MIRM stock closed at 100.90 USD on the Nasdaq Global Market at 4:00:00 PM Eastern Time in the most recent trading session, with an unchanged after hours indication at the same level as of 4:10:04 PM Eastern Time.

An additional reference in the Madrigal Pharmaceuticals analyst overview on Yahoo Finance lists MIRM at 100.90 USD with a 0.27 percent gain, underlining that the stock is trading close to the psychological 100 dollar mark as of early September 2026.

The MarketBeat coverage explains that Mirum Pharmaceuticals has a negative return on equity of 36.28 percent and a negative net margin of 139.18 percent, which investors will weigh against the strong sales growth and the expectation that earnings per share may improve over the course of 2026.

Key product focus in rare liver diseases

Mirum Pharmaceuticals focuses on therapies for rare liver diseases and cholestatic conditions, including products such as its bile acid modulation treatments that target severe pruritus and progressive liver damage in pediatric and adult patients.

These therapies aim to convert the strong revenue momentum visible in the 176.24 million USD second quarter 2026 sales figure into sustainable long term growth, as physicians gradually adopt Mirum's treatments in clinical practice for hard to treat indications.

MIRM stock price and investor view

For investors tracking MIRM stock, the most recent price snapshot from Yahoo Finance as of the close on September 4, 2026 shows Mirum Pharmaceuticals at 100.90 USD per share on the Nasdaq Global Market, with a modest 0.27 percent daily gain and an after hours indication at the same level.

Mirum Pharmaceuticals key data

• Company: Mirum Pharmaceuticals, Inc.
• ISIN: US60471A1034
• Ticker: MIRM
• Trading venue: Nasdaq Global Market
• Price (as of September 4, 2026, 16:00): 100.90 USD
• Market capitalization: not specified (as of latest available data)
• Sector / Industry: Health Care / Biotechnology
• Index membership: not specified major index